Axite has secured €250,000 in Takeoff 2 early-stage funding, a significant step forward in their journey of innovation and growth. Meanwhile, 1NA has been honored with the prestigious 2025 CES Innovation Award, recognizing their outstanding contributions to technology and health.
These milestones reflect the spirit of ambition and innovation that defines our Leiden Bio Science Park community. Congratulations to both teams—here’s to an exciting future ahead!.
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.